{"nctId":"NCT03164928","briefTitle":"Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis","startDateStruct":{"date":"2018-05-07","type":"ACTUAL"},"conditions":["Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With","Glucocorticoid-induced Osteoporosis"],"count":24,"armGroups":[{"label":"Placebo","type":"OTHER","interventionNames":["Other: Placebo"]},{"label":"Denosumab","type":"EXPERIMENTAL","interventionNames":["Drug: Denosumab"]}],"interventions":[{"name":"Denosumab","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects, age 5 to 17 years, inclusive, at the time of informed consent.\n* Clinical diagnosis of GiOP as defined by the following (and consistent with the International Society for Clinical Densitometry definition of osteoporosis in children and adolescents \\[Bishop et al, 2014\\])\n* A confirmed diagnosis of non-malignant condition(s) requiring treatment with systemic GC (including, but not limited to, chronic rheumatologic, gastrointestinal, neurologic, respiratory, and/or nephrological conditions)\n* Subjects who are on systemic GC only as replacement therapy for adrenal insufficiency are not eligible for the study - Treatment with systemic GC (intravenous or oral) of any duration for the underlying non-malignant condition(s) within the 12 months prior to screening\n* Evidence of at least 1 vertebral compression fracture of Genant grade 1 or higher, as assessed by the central imaging vendor on lateral spine X-rays performed at screening or within 2 months prior to screening; OR, in the absence of vertebral compression fractures, presence of both clinically significant fracture history (ie, ≥ 2 long-bone fractures by age 10 years or ≥ 3 long-bone fractures at any age up to 17 years) and lumbar spine BMD Z-score ≤ -2.0, as assessed by the central imaging vendor.\n\n  • Subject's legally acceptable representative has provided informed consent when the subject is legally too young to provide informed consent and the subject has provided assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated\n* A confirmed diagnosis of non-malignant condition(s) requiring treatment with systemic GC (including, but not limited to, chronic rheumatologic, gastrointestinal, neurologic, respiratory, and/or nephrological conditions)\n* Subjects who are on systemic GC only as replacement therapy for adrenal insufficiency are not eligible for the study\n* Treatment with systemic GC (intravenous or oral) of any duration for the underlying non malignant condition(s) within the 12 months prior to screening\n* Prepubertal children should be expected to require significant GC use during the study, per investigator opinion\n\nExclusion criteria will include the following:\n\n* Current hyperthyroidism (unless well controlled on stable antithyroid therapy)\n* Current clinical hypothyroidism (unless well controlled on stable thyroid replacement therapy)\n* History of hyperparathyroidism\n* Current hypoparathyroidism\n* Duchenne muscular dystrophy with symptomatic cardiac abnormality\n* Current malabsorption\n* Active infection or history of infections\n* History of malignancy\n\n  * Any causes of primary or secondary osteoporosis (other than GC use), or previous exposure to non-GC medications, which the investigator considers to have been a major factor contributing to the patient's fracture(s)\n  * Current adrenal insufficiency as the sole indication for GC therapy\n  * Duchenne muscular dystrophy with symptomatic cardiac abnormality\n  * Current malabsorption (in children with serum albumin -lower limit of normal \\[LLN\\], malabsorption should be clinically ruled out by the investigator to confirm eligibility)\n  * Known intolerance to calcium or vitamin D supplements\n  * Active infection or history of infections, defined as follows:\n* Any active infection for which systemic anti-infectives were used within 4 weeks prior to screening\n* Serious infection, defined as requiring hospitalization or intravenous anti infectives within 8 weeks prior to screening\n* Recurrent or chronic infection or other active infection that, in the opinion of the investigator, might compromise the safety of the subject","healthyVolunteers":false,"sex":"ALL","minimumAge":"5 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Lumbar Spine BMD Z-score as Assessed by Dual-energy X-ray Absorptiometry (DXA) at 12 Months","description":"Lumbar spine BMD was assessed by DXA and analyzed by analysis of covariance (ANCOVA) including treatment (denosumab vs placebo), baseline age, and baseline BMD z-score. DXA results were converted to z-scores, indicating number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify lumbar spine BMD improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":null},{"groupId":"OG001","value":"0.11","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lumbar Spine BMD Z-score as Assessed by DXA at 6, 18, 24, and 36 Months","description":"Lumbar spine BMD was assessed by DXA and analyzed by repeated measures analysis with randomization group, visit, baseline age, and baseline BMD z-score as fixed effects. Treatment-by-visit was included as an interaction term. DXA results were converted to z-scores, indicating number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify lumbar spine BMD improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":null},{"groupId":"OG001","value":"0.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":null},{"groupId":"OG001","value":"0.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":null},{"groupId":"OG001","value":"0.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.23","spread":null},{"groupId":"OG001","value":"0.57","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Proximal Femur BMD Z-score as Assessed by DXA at 6, 12, 18, 24, and 36 Months","description":"Proximal femur (total hip and femoral neck) BMD was assessed by DXA and analyzed by repeated measures analysis with randomization group, visit, baseline age, and baseline BMD z-score as fixed effects. Treatment-by-visit was included as an interaction term. DXA results were converted to z-scores, indicating number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify proximal femur BMD improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":null},{"groupId":"OG001","value":"0.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":null},{"groupId":"OG001","value":"0.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":null},{"groupId":"OG001","value":"0.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":null},{"groupId":"OG001","value":"0.69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.64","spread":null},{"groupId":"OG001","value":"0.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":null},{"groupId":"OG001","value":"0.60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":null},{"groupId":"OG001","value":"0.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":null},{"groupId":"OG001","value":"0.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":null},{"groupId":"OG001","value":"0.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null},{"groupId":"OG001","value":"0.63","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With X-ray Confirmed Long-bone Fractures and/or Vertebral Fractures at 12, 24, and 36 Months","description":"Number of participants who have at least one long bone fracture or vertebral fracture, and number of participants who have more than one long bone fracture or vertebral fracture.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improving Vertebral Fractures at 12, 24, and 36 Months","description":"Number of participants with improving vertebral fractures. An improving fracture is defined as one showing signs of healing/repair from baseline as assessed by X-ray.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With New and Worsening Vertebral and Non-vertebral Fractures at 12, 24, and 36 Months","description":"Number of participants who have at least one vertebral fracture or non-vertebral fracture, and number of participants who have more than one vertebral fracture or non-vertebral fracture.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Child Health Questionnaire-Parent Form-50 (CHQ-PF-50) Physical Summary Score at 12, 24, and 36 Months","description":"The CHQ-PF-50 is a 50-item questionnaire to be completed by the parents or guardians of children between 5 and 18 years of age. The physical summary score ranges from 0-100 with higher scores indicating better physical health.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.26","spread":"8.88"},{"groupId":"OG001","value":"8.53","spread":"16.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.62","spread":"7.39"},{"groupId":"OG001","value":"19.88","spread":"15.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.48","spread":"8.89"},{"groupId":"OG001","value":"14.18","spread":"8.14"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CHQ-PF-50 Psychological Summary Score at 12, 24, and 36 Months","description":"The CHQ-PF-50 is a 50-item questionnaire to be completed by the parents or guardians of children between 5 and 18 years of age. The psychological summary score ranges from 0-100 with higher scores indicating better psychological health.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":"9.15"},{"groupId":"OG001","value":"-0.10","spread":"12.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.58","spread":"12.58"},{"groupId":"OG001","value":"1.90","spread":"9.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.20","spread":"10.09"},{"groupId":"OG001","value":"2.00","spread":"9.33"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index Score at 12, 24, and 36 Months","description":"The CHAQ was developed to measure the physical functioning in children 6 months to 18 years of age. It consists of 54 questions related to the child's ability to perform various activities of daily living. Depending on the question asked, each question is scored either 0 to 3 based on the level of difficulty experienced by the child or 0-1 based on whether the child required assistance from another person or used an aid or other device. All CHAQ questions were scored and converted to a total index score ranging from 0-3, where higher scores indicate greater disability.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.32"},{"groupId":"OG001","value":"-0.29","spread":"0.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.33"},{"groupId":"OG001","value":"-0.30","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"0.45"},{"groupId":"OG001","value":"-0.43","spread":"0.45"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Wong-Baker FACES Pain Rating Scale (WBFPRS) at 12, 24, and 36 Months","description":"The WBFPRS is a horizontal pain scale for children 3-18 years which consists of 6 faces that range from a smiling \"no hurt\" face with a score of 0 to a crying \"hurts worst\" face with a score of 10.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"3.3"},{"groupId":"OG001","value":"-0.3","spread":"3.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"2.9"},{"groupId":"OG001","value":"-2.4","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"1.8"},{"groupId":"OG001","value":"0.0","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Growth Velocity Z-score (Height) at 12, 24, and 36 Months","description":"Growth velocity was determined by calculating age-adjusted z-scores for height, weight, and body mass index (BMI). Z-scores represent the number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify increased growth velocity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"0.46"},{"groupId":"OG001","value":"-0.07","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.90"},{"groupId":"OG001","value":"-0.27","spread":"1.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":"0.84"},{"groupId":"OG001","value":"0.01","spread":"1.35"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Growth Velocity Z-score (Weight) at 12, 24, and 36 Months","description":"Growth velocity was determined by calculating age-adjusted z-scores for height, weight, and BMI. Z-scores represent the number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify increased growth velocity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"0.44"},{"groupId":"OG001","value":"-0.10","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"0.73"},{"groupId":"OG001","value":"-0.68","spread":"0.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":"0.90"},{"groupId":"OG001","value":"-0.44","spread":"0.60"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Growth Velocity Z-score (BMI) at 12, 24, and 36 Months","description":"Growth velocity was determined by calculating age-adjusted z-scores for height, weight, and BMI. Z-scores represent the number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify increased growth velocity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.53"},{"groupId":"OG001","value":"-0.14","spread":"0.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"0.80"},{"groupId":"OG001","value":"-0.75","spread":"1.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"0.84"},{"groupId":"OG001","value":"-0.72","spread":"0.97"}]}]}]},{"type":"SECONDARY","title":"Mean Serum Concentration of Denosumab","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10300","spread":"7900"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6830","spread":"4770"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1100","spread":"935"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":"338"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":"349"},{"groupId":"OG001","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":"154"},{"groupId":"OG001","value":"7.61","spread":"21.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":8},"commonTop":["Headache","Anaemia","Nasopharyngitis","Back pain","Tachycardia"]}}}